Enhancing alopecia areata management: Nanocrystal-driven strategy for targeting hair follicles

Alopecia areata (AA) is an autoimmune disorder that disrupts the hair growth cycle, leading to non-scarring hair loss. In AA, hair follicles (HFs) serve as both pathological targets and potential drug delivery sites when treated with optimized topical formulations. This study investigates the follicular targeting efficiency of clobetasol-17-propionate (CP) nanocrystal (CP-NC) suspension, a nanoformulation designed to enhance the efficacy of conventional CP therapies by improving kinetic solubility and creating a steep concentration gradient that promotes passive dermal penetration. Once delivered to the HFs, CP-NC suspensions function as localized depots, ensuring sustained drug release and prolonged therapeutic effects. To this end, CP was reduced to nanocrystalline dimensions (particle size, 210.7 ± 4.8 nm; polydispersity index, 0.205 ± 0.01; zeta potential, -30.50 ± 1.9 mV) through a hybrid approach combining bottom-up (controlled precipitation) and top-down (high-pressure homogenization) techniques. To enhance clinical applicability, CP-NC suspensions were incorporated into a gel matrix (CP-NC-Gel), extending scalp contact time and improving formulation stability. Both stratum corneum and dermal drug deposition were significantly higher with CP-NC-Gel than conventional CP gel (CP-Gel), confirming its effectiveness in targeting both superficial and deep skin layers. Moreover, ex vivo skin permeability tests revealed a 4-fold increase in follicular drug deposition with CP-NC-Gel compared to CP-Gel, attributed to improved HF penetration and retention. By enhancing the follicular bioavailability of CP while minimizing systemic exposure, CP-NC-Gel addresses the common challenges of efficacy and safety associated with traditional glucocorticoid therapies. Furthermore, its sustained release profile reduces dosing frequency, which ultimately improves patient compliance.